Lazaros Andronis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1436430/publications.pdf

Version: 2024-02-01

706676 620720 36 723 14 26 citations g-index h-index papers 36 36 36 1425 docs citations times ranked citing authors all docs

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Procedural and 12-month in-hospital costs of primary infra-popliteal bypass surgery, infrapopliteal best endovascular treatment, and major lower limb amputation for chronic limb threatening ischemia. Journal of Vascular Surgery, 2022, 75, 195-204. | 0.6 | 9 |
| 2 | Economic costs at age five associated with very preterm birth: multinational European cohort study. Pediatric Research, 2022, 92, 700-711. | 1.1 | 3 |
| 3 | REducing Colonoscopies in patients without significant bowEl DiseasE: the RECEDE Study - protocol for a prospective diagnostic accuracy study. BMJ Open, 2022, 12, e058559. | 0.8 | 2 |
| 4 | High Healthcare Use at Age 5ÂYears in a European Cohort of Children Born Very Preterm. Journal of Pediatrics, 2022, 243, 69-77.e9. | 0.9 | 8 |
| 5 | B06 What is the best location for a defibrillator to improve OHCA coverage?. Resuscitation, 2022, 175, S4. | 1.3 | O |
| 6 | Micronutrient deficiencies and health-related quality of life: the case of children with vitamin D deficiency. Public Health Nutrition, 2020, 23, 1165-1172. | 1.1 | 7 |
| 7 | The PLANES study: a protocol for a randomised controlled feasibility study of the placental growth factor (PIGF) blood test-informed care versus standard care alone for women with a small for gestational age fetus at or after 32 + 0 weeks' gestation. Pilot and Feasibility Studies, 2020, 6, 179. | 0.5 | 4 |
| 8 | Will the US\$5 million onasemnogene abeparvosec treatment for spinal muscular atrophy represent †value for money†for the NHS? A rapid inquiry into suggestions that it may be cost-effective. Expert Opinion on Biological Therapy, 2020, 20, 823-827. | 1.4 | 9 |
| 9 | Measuring, valuing and including forgone childhood education and leisure time costs in economic evaluation: Methods, challenges and the way forward. Social Science and Medicine, 2019, 237, 112475. | 1.8 | 11 |
| 10 | Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials. BMC Cancer, 2019, 19, 392. | 1.1 | 7 |
| 11 | Are acceptance and mindfulnessâ€based interventions †value for money'? Evidence from a systematic literature review. British Journal of Clinical Psychology, 2019, 58, 187-210. | 1.7 | 24 |
| 12 | Three wound-dressing strategies to reduce surgical site infection after abdominal surgery: the Bluebelle feasibility study and pilot RCT. Health Technology Assessment, 2019, 23, 1-166. | 1.3 | 10 |
| 13 | Intrathecal Drug Delivery Systems for the Management of Chronic Noncancer Pain: A Systematic Review of Economic Evaluations. Pain Practice, 2018, 18, 666-686. | 0.9 | 12 |
| 14 | Cost-Effectiveness of Treatments for the Management of Bone Metastases: A Systematic Literature Review. Pharmacoeconomics, 2018, 36, 301-322. | 1.7 | 15 |
| 15 | Is the Venner-PneuX Endotracheal Tube System a Cost-Effective Option for Post Cardiac Surgery Care?. Annals of Thoracic Surgery, 2018, 106, 757-763. | 0.7 | 4 |
| 16 | Cost of treating ventilator-associated pneumonia post cardiac surgery in the National Health Service: Results from a propensity-matched cohort study. Journal of the Intensive Care Society, 2018, 19, 94-100. | 1.1 | 20 |
| 17 | Costâ€effectiveness of zoledronic acid and strontiumâ€89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrateâ€refractory prostate cancer: results from the <scp>TRAPEZE</scp> trial (<scp>ISRCTN</scp> 12808747). BJU International, 2017, 119, 522-529. | 1.3 | 18 |
| 18 | Preventing vitamin D deficiency (VDD): a systematic review of economic evaluations. European Journal of Public Health, 2017, 27, 292-301. | 0.1 | 24 |

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Rationale and design of BISTRO: a randomized controlled trial to determine whether bioimpedance spectroscopy-guided fluid management maintains residual kidney function in incident haemodialysis patients. BMC Nephrology, 2017, 18, 138. | 0.8 | 17 |
| 20 | BAlloon versus Stenting in severe Ischaemia of the Leg-3 (BASIL-3): study protocol for a randomised controlled trial. Trials, 2017, 18, 224. | 0.7 | 59 |
| 21 | Cost-Effectiveness of Non-Invasive and Non-Pharmacological Interventions for Low Back Pain: a Systematic Literature Review. Applied Health Economics and Health Policy, 2017, 15, 173-201. | 1.0 | 64 |
| 22 | Setting Medical Research Future Fund priorities: assessing the value of research. Medical Journal of Australia, 2017, 206, 63-65. | 0.8 | 9 |
| 23 | A mixed-methods feasibility and external pilot study to inform a large pragmatic randomised controlled trial of the effects of surgical wound dressing strategies on surgical site infections (Bluebelle Phase B): study protocol for a randomised controlled trial. Trials, 2017, 18, 401. | 0.7 | 13 |
| 24 | Intrathecal drug delivery systems for the management of chronic non-cancer pain: protocol for a systematic review of economic evaluations. BMJ Open, 2016, 6, e012285. | 0.8 | 8 |
| 25 | Adjusting Expected Value of Sample Information Using Realistic Expectations around Implementation. Medical Decision Making, 2016, 36, 284-284. | 1.2 | 1 |
| 26 | Bypass versus angio plasty in severe ischaemia of the leg - 2 (BASIL-2) trial: study protocol for a randomised controlled trial. Trials, 2016, 17, 11. | 0.7 | 134 |
| 27 | Choice of statistical model for cost-effectiveness analysis and covariate adjustment: empirical application of prominent models and assessment of their results. European Journal of Health Economics, 2016, 17, 927-938. | 1.4 | 20 |
| 28 | Interpretation of the Expected Value of Perfect Information and Research Recommendations. Medical Decision Making, 2016, 36, 285-295. | 1.2 | 17 |
| 29 | Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both. JAMA Oncology, 2016, 2, 493. | 3.4 | 78 |
| 30 | Quality of life increases in patients with painful diabetic neuropathy following treatment with spinal cord stimulation. Quality of Life Research, 2016, 25, 1771-1777. | 1.5 | 32 |
| 31 | A Practical Application of Value of Information and Prospective Payback of Research to Prioritize Evaluative Research. Medical Decision Making, 2016, 36, 321-334. | 1.2 | 9 |
| 32 | Adjusting Estimates of the Expected Value of Information for Implementation. Medical Decision Making, 2016, 36, 296-307. | 1.2 | 22 |
| 33 | TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer. Health Technology Assessment, 2016, 20, 1-288. | 1.3 | 29 |
| 34 | Analytic approaches for research priority-setting: issues, challenges and the way forward. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 745-754. | 0.7 | 8 |
| 35 | Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer. (ISRCTN 12808747) TRAPEZE Journal of Clinical Oncology, 2015, 33, e16108-e16108. | 0.8 | 2 |
| 36 | Screening for sickle cell and thalassaemia in primary care: a cost-effectiveness study. British Journal of General Practice, 2011, 61, e620-e627. | 0.7 | 14 |